Charlie Nicholls

7PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)AutoimmunityBiomechanical engineeringMedical biochemistry - carbohydratesCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 28, 2025
Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States.

Kevin Hall, Aleksandr Lazaryan, Mark van der Laan

|Sep 02, 2022
Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.

William H Polonsky, Francesco Giorgino, Julio Rosenstock

|May 02, 2022
Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.

Timothy S Bailey, Jasvinder Gill, Merwyn Jones S

|Nov 22, 2021
Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.

Sean D Sullivan, Nick Freemantle, Rishab A Gupta

|Nov 25, 2020
How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?

Dídac Mauricio, Jukka Westerbacka, Charlie Nicholls

|Jul 12, 2019
Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting.

Fang L Zhou, Charlie Nicholls, Lin Xie

Pageof 2

Frequent Collaborators

2 joint publications

Jasmanda Wu

1 joint publications

Juan P Frias

1 joint publications

Fang L Zhou

1 joint publications

Luigi F Meneghini